Dumb Money Has Fled Rocket Lab Stock. Is It Finally Safe to Buy?

Rocket Lab shares, which surged as a momentum story earlier in 2025—peaking near $74 on Oct. 15 and up about 176% year-to-date—have tumbled roughly 38% to under $43 after CEO Peter Beck signaled the inaugural Neutron medium‑lift reusable launch will likely be delayed until early 2026; the setback threatens the company’s planned ramp in launch cadence and pushes out the anticipated path to GAAP profitability and positive free cash flow. Operationally the business remains strong (about 75 Electron launches to date with ~93% success, expected ~20 launches this year, 15x revenue growth over five years and a 32% gross margin), but the stock still trades at a rich valuation—nearly $23 billion market cap on $555 million trailing sales, roughly a 40x price-to-sales multiple—leaving limited margin for execution slippage and making analysts wary of endorsing buys. The practical implication for investors is increased downside risk and a need for proof of execution or a lower price before adding exposure; the author discloses he remains a holder but will not add shares until Rocket Lab posts GAAP profitability or the shares meaningfully drop further.

Analysis

Rocket Lab shares surged earlier in 2025, peaking near $74 on Oct. 15 and rising about 176% year-to-date, but the stock retraced roughly 38% to under $43 after CEO Peter Beck said the inaugural Neutron medium‑lift reusable launch will likely be delayed until early 2026, triggering a rapid momentum unwind following the company’s post-earnings move. The company’s operational record remains intact: Rocket Lab has completed about 75 Electron launches with ~93% success, expects at least 20 launches this year, has grown revenue ~15x over five years and flipped to gross profit with a 32% gross margin. Neutron’s slip matters for the timeline to profitability because analysts had expected Neutron-driven scale to deliver GAAP profitability and positive free cash flow by 2027; management now admits that cadence and profitability are likely pushed out by roughly a year. Valuation is the key risk: a nearly $23 billion market capitalization on $555 million trailing sales implies roughly a 40x price-to-sales multiple (the article also cites a 63x multiple pre-earnings), meaning the stock was priced for perfection and now faces material downside if execution or timing disappoints.

Key Decisions for Investors

• Do not add to core positions until Rocket Lab either achieves GAAP profitability or produces verifiable Neutron flight milestones, as the current valuation (~40x P/S) leaves little room for further slippage.
• If seeking exposure, limit size to a speculative sleeve or use asymmetric option strategies (protective puts or defined-risk calls) to cap downside while retaining upside optionality.
• Monitor catalysts closely: management updates on Neutron schedule, quarterly launch cadence guidance, and any changes to the 2027 profitability/FCF target, and be prepared to re-evaluate on confirmed progress.
• Existing shareholders should consider trimming or hedging into rallies given the loss of momentum and heightened probability of additional drawdowns absent clear execution catalysts.